Your browser doesn't support javascript.
Use of disease-modifying drugs (tocilizumab, tofacitinib, and baricitinib-a biological or synthetic target specific) in patients hospitalized with COVID-19.
Barbosa, Alexandre Naime; Silvinato, Antonio; Bacha, Hélio; Floriano, Idevaldo; Tanni, Suzana; Bernardo, Wanderley.
  • Barbosa AN; Universidade Estadual Paulista, Faculdade de Medicina de Botucatu, Departamento de Infectologia - Botucatu (SP), Brazil.
  • Silvinato A; Associação Médica Brasileira, Medicina Baseada em Evidências - São Paulo (SP), Brazil.
  • Bacha H; Hospital Israelita Albert Einstein - São Paulo (SP), Brazil.
  • Floriano I; Cooperativa Baixa Mogiana, Medicina Baseada em Evidências - Mogi Guaçu (SP), Brazil.
  • Tanni S; Universidade Estadual Paulista, Faculdade de Medicina de Botucatu, Departamento de Clínica Médica, Disciplina de Pneumologia - Botucatu (SP), Brazil.
  • Bernardo W; Associação Médica Brasileira, Medicina Baseada em Evidências - São Paulo (SP), Brazil.
Rev Assoc Med Bras (1992) ; 68(1): 3-8, 2022 01.
Article in English | MEDLINE | ID: covidwho-1974439
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antirheumatic Agents / COVID-19 Drug Treatment Limits: Humans Language: English Journal: Rev Assoc Med Bras (1992) Year: 2022 Document Type: Article Affiliation country: 1806-9282.2022D681

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antirheumatic Agents / COVID-19 Drug Treatment Limits: Humans Language: English Journal: Rev Assoc Med Bras (1992) Year: 2022 Document Type: Article Affiliation country: 1806-9282.2022D681